HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
Read original at benzingaStocks · News reference
Elicio Therapeutics Announces Opening Of 20-Patient Investigator-Initiated Phase 1 Trial Of ELI-002 7P With Chemotherapy, Anti-PD1 In Neoadjuvant Pancreatic Cancer At Memorial Sloan Kettering
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 12:06 PM
- Checked
- Aug 10, 2026, 12:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share
Read original at benzinga8-K filing — Elicio Therapeutics, Inc. (ELTX)
Filed: 2026-08-13 AccNo: 0001601485-26-000055 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar